INFORMATION FOR PATIENTS

PRECISION1

A Clinical Trial for Patients with Advanced Solid Tumors with Certain Gene Alterations

ADI bioscience



What is a Clinical Trial?

A clinical trial is a way for people in the medical community to find out if a treatment is **safe and effective** to treat a medical problem like cancer.

Clinical trials involve the **treating doctors and medical team** at a specific clinic participating in the clinical trial, plus the **study team** from the company that makes the treatment, and **health authorities** like the Food and Drug Administration (FDA).

After the **clinical trial is completed**, and if the treatment works and is safe, the information from the clinical trial is given to the FDA. **FDA then carefully reviews the information** and makes a decision whether or not to approve the treatment for the disease that was studied in the clinical trial.

What is the PRECISION 1 trial?

Aadi Bioscience is sponsoring the **PRECISION 1 trial** to investigate whether an investigational medication called *nab*-sirolimus can help treat people with advanced solid tumors that have alterations in their *TSC1* or *TSC2* genes. The safety and efficacy of *nab*-sirolimus for this use have not been established.

What are the *TSC1* and *TSC2* genes?

The ***TSC1* and *TSC2* genes** are part of something called the mTOR pathway.

mTOR is a protein that helps to control the growth of both normal and cancer cells. *TSC1*, *TSC2*, and other genes in the mTOR pathway work together to control the mTOR pathway.

Loss of *TSC1* or *TSC2* leads to overactive mTOR, resulting in uncontrolled growth of cancer cells.

How likely is it that I have a *TSC1* or *TSC2* alteration?

These alterations occur in different percentages in various types of cancer, including:

8.1%-9.8%

BLADDER CANCER

2.0%-2.2%

SOFT TISSUE SARCOMA

5.2%-5.9%

KIDNEY CANCER

0.8%-1.3%

THYROID CANCER



5.3%-6.6%

LIVER CANCER

1.2%-2.2%

OVARIAN CANCER



1.4%-2.2%

MELANOMA

1.1%-1.2%

CERVICAL CANCER

4.3%-4.6%

ENDOMETRIAL CARCINOMA

1.5%-2.2%

NON-SMALL CELL LUNG CANCER

1.5%-1.6%

COLORECTAL CANCER

0.4%-0.5%

PANCREATIC CANCER

Talk to your doctor about whether you may have a *TSC1* or *TSC2* mutation. A next generation sequencing (NGS) test can show whether or not the *TSC1* or *TSC2* genes have a qualifying mutation for the PRECISION 1 study.

Who Is Eligible for the trial?

To be eligible for the PRECISION 1 trial, a patient must:

- Be at least 12 years old
- Have not used any other mTOR inhibitors (for example, everolimus or temsirolimus)
- Be able to perform normal daily activities (measured by a doctor using certain scales)
- Have a solid tumor with the *TSC1* or *TSC2* mutation that is metastatic or cannot be surgically removed
- Have received all other appropriate standard treatment options for their tumor type and stage of disease

To determine whether you have a *TSC1* or *TSC2* mutation, a doctor will have the tumor analyzed using a technology called **next generation sequencing (NGS)**.

What happens during the trial?

All participants in the **PRECISION 1** trial will receive the study drug, *nab*-sirolimus, on day 1 and day 8, and then take a week off. Then the 21 day cycle repeats: Once a week for 2 weeks followed by 1 week off. The drug is given by an intravenous (IV) infusion, which takes about 30 minutes.



If you do not tolerate the drug well, your doctor may decide to try a lower dose. You will continue to receive the drug until your disease progresses, you experience unacceptable side effects, or you choose to stop participating.

For more information about the PRECISION 1 trial, visit **Precision1TrialInfo.com**

mTOR=mechanistic target of rapamycin; nab=nanoparticle albumin-bound; *TSC1*=tuberous sclerosis 1; *TSC2*=tuberous sclerosis 2

About Aadi Bioscience

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.

mission

Learn more about Aadi Bioscience at **aadibio.com**

US-MED-2300035 11/2023